durvalumab,oleclumab
astrazeneca
['breast', 'synergy', 'durva', 'oleclumab', 'tnbc', 'increase,(-increased)']
#esmo22 updates: addition of oleclumab (anti-cd73) to durvalumab + chemo combo in synergy ph2 trial did not increase cbr and pfs in 1l tnbc - adds up to the list of failures in the space of io
#solidtumors #immunooncology #oncology #immunotherapy #breastcancer #cancer 
Course5i prides itself in enabling #LifeSciences organizations with insights, #analytics and #AI to drive strategic decisions. Enabling better health outcomes.